8-K: Heron Therapeutics Reports Positive Adjusted EBITDA and Narrows 2024 Financial Guidance

Heron Therapeutics announced positive year-to-date adjusted EBITDA and narrowed its full-year 2024 financial guidance, driven by revenue growth and financial management.

Summary

• Heron Therapeutics reported its financial results for the three and nine months ended September 30, 2024.
• The company achieved positive adjusted EBITDA of $1.4 million year-to-date in 2024.
• Heron has narrowed its full-year 2024 guidance for product revenues to $140.0 to $146.0 million, adjusted operating expenses to $101.0 to $105.0 million, and adjusted EBITDA to $2.0 to $5.0 million.
• The ZYNRELEF Vial Access Needle (VAN) was approved in September and is on track for a Q4 2024 launch.
• ZYNRELEF is included in the CMS Final Rule Non-Opioid Policy for Pain Relief, qualifying it for separate payment in hospital outpatient and ambulatory surgical center settings.
• Cash and cash equivalents were $70.9 million as of September 30, 2024, compared to $80.4 million at the end of 2023.
• Acute care franchise net product sales were $7.4 million for the quarter and $19.7 million for the nine months ended September 30, 2024.
• ZYNRELEF net product sales were $6.3 million for the quarter and $17.1 million for the nine months ended September 30, 2024.
• Oncology care franchise net product sales were $25.4 million for the quarter and $83.8 million for the nine months ended September 30, 2024.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the achievement of positive adjusted EBITDA, narrowed financial guidance, and the approval of the ZYNRELEF VAN. However, the company still reported a net loss and a decrease in cash reserves, which tempers the overall optimism.

Positives

• The company achieved positive adjusted EBITDA year-to-date, indicating improved financial performance.
• The narrowing of financial guidance suggests increased confidence in achieving targets.
• The approval and upcoming launch of the ZYNRELEF VAN is expected to simplify preparation and reduce withdrawal time.
• Inclusion of ZYNRELEF in the CMS Non-Opioid Policy for Pain Relief ensures separate payment and supports market growth.
• Sales of both acute care and oncology products have increased compared to the same period in 2023.
• The company has demonstrated prudent financial management and continued revenue growth.

Negatives

• The company's cash and cash equivalents decreased from $80.4 million at the end of 2023 to $70.9 million as of September 30, 2024.
• The company reported a net loss of $4.8 million for the quarter and $17.2 million for the nine months ended September 30, 2024.
• Cost of product sales was $9.4 million for the quarter and $28.4 million for the nine months ended September 30, 2024.

Risks

• The company's future performance is subject to risks and uncertainties, including market opportunities, regulatory approvals, and commercial arrangements.
• There is a risk that the company may need future equity financings.
• The company's ability to achieve profitability is not guaranteed.
• The company is subject to litigation risk.

Future Outlook

The company expects Q4 2024 net revenue in the range of $37 million to $43 million and has narrowed its full-year 2024 guidance for product revenues, adjusted operating expenses, and adjusted EBITDA.

Management Comments

• We are pleased to report that with our prudent financial management and continued revenue growth we were able to achieve positive Adjusted EBITDA for the quarter, said Craig Collard, Chief Executive Officer.
• The future looks bright as we continue to grow all product revenue.
• We continue to deliver on our commitment to financial efficiency while growing revenue.
• The team has made great strides in the transformation of Heron over the past year.
• We are looking forward to a strong fourth quarter which is off to a great start.

Industry Context

The inclusion of ZYNRELEF in the CMS Non-Opioid Policy for Pain Relief reflects a broader industry trend towards non-opioid pain management alternatives. This policy is expected to encourage the use of non-opioid options like ZYNRELEF, potentially increasing its market share.

Comparison to Industry Standards

• Heron's focus on non-opioid pain management aligns with the industry's shift away from opioids, similar to companies like Pacira BioSciences, which also offers non-opioid pain solutions.
• The separate payment status for ZYNRELEF under the CMS policy is a significant advantage, comparable to how other innovative medical products receive favorable reimbursement.
• The company's adjusted EBITDA performance is a key metric, and its positive result is a positive sign compared to other biotech companies that are still in the development phase.
• The launch of the ZYNRELEF VAN is similar to other companies introducing new delivery methods to improve product usability and efficiency.

Stakeholder Impact

• Shareholders will likely view the positive adjusted EBITDA and narrowed guidance favorably.
• Employees may be encouraged by the company's improved financial performance and future outlook.
• Customers will benefit from the launch of the ZYNRELEF VAN, which simplifies preparation and reduces withdrawal time.
• The inclusion of ZYNRELEF in the CMS Non-Opioid Policy for Pain Relief may increase demand for the product.

Next Steps

• The company will launch the ZYNRELEF VAN in Q4 2024.
• The company will continue to focus on growing product revenue.
• The company will continue to manage its financial efficiency.

Key Dates

Keywords

ZYNRELEF, APONVIE, CINVANTI, SUSTOL, EBITDA, Financial Guidance, CMS, Non-Opioid, Pain Relief, Vial Access Needle, Pharmaceuticals, Biotechnology